XSHE
300519
Market cap340mUSD
Jul 10, Last price
15.35CNY
1D
-0.13%
1Q
19.41%
Jan 2017
-62.32%
IPO
57.89%
Name
Zhejiang Xinguang Pharmaceutical Co Ltd
Chart & Performance
Profile
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health foods. The company offers pharmaceutical products in the areas of cardiovascular and cerebrovascular diseases, and traumatic diseases, covering the aspects of respiratory system, digestive system, urinary system, pediatric diseases, and improving immunity. It also can produce 6 dosage forms with 49 approval numbers for drug production and 2 approval numbers for health food. It offers its products in the form of tablets, granules, syrups, powders, hard capsules, and oral solutions, as well as mixtures, including oral liquids. Zhejiang Xinguang Pharmaceutical Co., Ltd. was founded in 1970 and is headquartered in Shengzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 270,400 -23.07% | 351,489 9.54% | |||||||
Cost of revenue | 196,248 | 221,237 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 74,152 | 130,251 | |||||||
NOPBT Margin | 27.42% | 37.06% | |||||||
Operating Taxes | 8,804 | 16,783 | |||||||
Tax Rate | 11.87% | 12.88% | |||||||
NOPAT | 65,348 | 113,469 | |||||||
Net income | 64,356 -40.86% | 108,821 -4.78% | |||||||
Dividends | (80,000) | (96,000) | |||||||
Dividend yield | 3.00% | 3.83% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | (145) | ||||||||
Long-term debt | 1 | ||||||||
Deferred revenue | 6,842 | 7,708 | |||||||
Other long-term liabilities | 2,362 | 2,362 | |||||||
Net debt | (720,341) | (737,174) | |||||||
Cash flow | |||||||||
Cash from operating activities | 53,290 | 126,429 | |||||||
CAPEX | (15,987) | ||||||||
Cash from investing activities | (51,374) | ||||||||
Cash from financing activities | (80,000) | (96,000) | |||||||
FCF | 50,851 | 113,262 | |||||||
Balance | |||||||||
Cash | 698,946 | 737,030 | |||||||
Long term investments | 21,396 | ||||||||
Excess cash | 706,821 | 719,455 | |||||||
Stockholders' equity | 570,908 | 697,606 | |||||||
Invested Capital | 282,417 | 148,185 | |||||||
ROIC | 30.35% | 73.54% | |||||||
ROCE | 8.69% | 15.39% | |||||||
EV | |||||||||
Common stock shares outstanding | 160,891 | 160,000 | |||||||
Price | 16.57 5.81% | 15.66 -22.44% | |||||||
Market cap | 2,665,967 6.40% | 2,505,600 -22.44% | |||||||
EV | 1,945,626 | 1,768,426 | |||||||
EBITDA | 88,926 | 144,306 | |||||||
EV/EBITDA | 21.88 | 12.25 | |||||||
Interest | 16 | 14 | |||||||
Interest/NOPBT | 0.02% | 0.01% |